SCHEMBL5031322

SCHEMBL5031322

CCCc1nc2c(N)nc(C)c(C)c2n1CC(C)(C)NS(C)(=O)=O

nearest known ligand 0.40

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 18/20 0.40
TLR8 Q9NR97 9/20 0.36
NUDT1 P36639 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5031335 0.94 TLR7 (0.44) TLR7TLR8
SCHEMBL6721708 0.86 TLR7 (0.46) TLR7TLR8NUDT1
SCHEMBL544239 0.80 TLR7 (0.61) TLR7TLR8NUDT1
SCHEMBL4794307 0.77 TLR7 (0.39) TLR7TLR8
SCHEMBL5031379 0.77 TLR7 (0.46) TLR7TLR8
SCHEMBL4793155 0.76 TLR7 (0.41) TLR7TLR8
SCHEMBL5030324 0.76
SCHEMBL6667771 0.75 TLR7 (0.44) TLR7TLR8NUDT1
SCHEMBL3862211 0.75 TLR7 (0.53) TLR7TLR8NUDT1
SCHEMBL4792774 0.75 TLR7 (0.41) TLR7TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080312434-A1 PROCESS FOR IMIDAZO [4,5-C] PYRIDIN-4-AMINES COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-12-18 US disclosed
US-20080312434-A1 PROCESS FOR IMIDAZO [4,5-C] PYRIDIN-4-AMINES COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-12-18 US disclosed
US-20080312434-A1 PROCESS FOR IMIDAZO [4,5-C] PYRIDIN-4-AMINES COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-12-18 US disclosed
US-20050032829-A1 Process for imidazo[4,5-c]pyridin-4-amines 3M INNOVATIVE PROPERTIES COMPANY 2005-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312434-A1 PROCESS FOR IMIDAZO [4,5-C] PYRIDIN-4-AMINES PAICS, HTR4, PNPO TLR7 974/4885TLR8 1214/4885NUDT1 322/4885
US-20050032829-A1 Process for imidazo[4,5-c]pyridin-4-amines PAICS, HTR4, PNPO TLR7 974/4885TLR8 1214/4885NUDT1 322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.